Approach Offers Regional Control of HPV-Related Head, Neck CA
FRIDAY, Feb. 9, 2018 -- Good regional control can be achieved with up-front surgery and adjuvant therapy for patients with invasive nodal disease from oropharyngeal squamous cell carcinoma (SCC) related to human papillomavirus (HPV), according to a study published online Jan. 29 in Head & Neck.
Joseph Zenga, M.D., from Washington University in Saint Louis, and colleagues assessed oncologic outcomes among 72 patients with HPV-related oropharyngeal SCC requiring resection of major muscular or neurovascular tissue during neck dissection for invasive nodal disease.
The researchers found that regional recurrences were seen in 6 percent of patients, and 17 percent experienced distant recurrences. Decreased disease-free survival was associated with advanced T classification, pathological node number ≥5, and omission of adjuvant therapy. However, adding adjuvant chemotherapy did not improve survival.
"In patients with HPV-related oropharyngeal SCC requiring resection of major muscular or neurovascular tissue due to invasive nodal disease, up-front surgical management with adjuvant therapy results in excellent long-term regional control," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: February 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.